RARE Stock - Ultragenyx Pharmaceutical Inc.
Unlock GoAI Insights for RARE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $560.23M | $434.25M | $363.33M | $351.41M | $271.03M |
| Gross Profit | $483.50M | $389.04M | $335.01M | $335.40M | $264.90M |
| Gross Margin | 86.3% | 89.6% | 92.2% | 95.4% | 97.7% |
| Operating Income | $-535,973,000 | $-569,208,000 | $-648,919,000 | $-381,737,000 | $-330,116,000 |
| Net Income | $-569,183,000 | $-606,639,000 | $-707,421,000 | $-454,025,000 | $-186,566,000 |
| Net Margin | -101.6% | -139.7% | -194.7% | -129.2% | -68.8% |
| EPS | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $65 |
| July 28th 2025 | H.C. Wainwright | Resumed | Buy | $80 |
| May 28th 2025 | William Blair | Initiation | Outperform | - |
| June 6th 2024 | Goldman | Upgrade | Buy | $67← $56 |
| April 22nd 2024 | RBC Capital Mkts | Initiation | Outperform | $77 |
| December 8th 2023 | Wells Fargo | Initiation | Overweight | $72 |
| June 14th 2023 | Credit Suisse | Resumed | Outperform | $96 |
| June 6th 2023 | Evercore ISI | Upgrade | Outperform | $80← $60 |
| April 26th 2023 | Cantor Fitzgerald | Initiation | Overweight | $114 |
| January 18th 2023 | Canaccord Genuity | Resumed | Buy | $90 |
| December 30th 2022 | H.C. Wainwright | Resumed | Buy | $82 |
| November 3rd 2022 | Robert W. Baird | Upgrade | Outperform | $50 |
| October 13th 2022 | Guggenheim | Upgrade | Buy | $50 |
| August 1st 2022 | Evercore ISI | Downgrade | In-line | $60← $95 |
Earnings History & Surprises
RAREEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-1.32 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-1.23 | $-1.81 | -47.2% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-1.27 | $-1.17 | +7.9% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.54 | $-1.57 | -1.9% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-1.32 | $-1.39 | -5.3% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-1.45 | $-1.40 | +3.4% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.64 | $-1.52 | +7.3% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-1.72 | $-2.03 | -18.0% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-1.65 | $-1.52 | +7.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-2.08 | $-2.23 | -7.2% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-2.11 | $-2.25 | -6.6% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.97 | $-2.33 | -18.3% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $-2.03 | $-2.16 | -6.4% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-2.29 | $-2.43 | -6.1% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $-1.72 | $-2.26 | -31.4% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.76 | $-2.19 | -24.4% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-1.32 | $-1.79 | -35.6% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-1.43 | $-1.08 | +24.5% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $-1.28 | $-1.45 | -13.3% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $50
➖ NeutralTD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $75
📈 PositiveTruist Securities Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $90
➖ NeutralUltragenyx Pharmaceutical shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeUltragenyx Pharmaceutical shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeUltragenyx Pharmaceutical Announces $400M Sale Of Additional 25% Royalty Interest From Kyowa Kirin On Future Sales Of Crysvita In U.S., Canada To OMERS
📈 PositiveUltragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.000M-$670.000M vs $657.157M Est
➖ NeutralUltragenyx Pharmaceutical Q3 EPS $(1.81) Misses $(1.25) Estimate, Sales $159.933M Miss $166.709M Estimate
📉 NegativeUltragenyx Doses First Patient In Aurora Study Evaluating GTX-102 In Additional Angelman Syndrome Genotypes And Age Groups
📈 PositiveHC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $80 Price Target
📈 PositiveUltragenyx Reports 96-Week Phase 3 Results For DTX401 In GSDIa, Showing Greater Reductions In Cornstarch Use And Sustained Glycemic Control
📈 PositiveCantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $105 Price Target
📈 PositiveUltragenyx Initiates Rolling Submission Of A Biologics License Application To The FDA For Its DTX401 AAV Gene Therapy In Glycogen Storage Disease Type Ia
📈 PositiveUltragenyx, Mereo in selloff after trial update on bone disorder therapy
📉 NegativeFrequently Asked Questions about RARE
What is RARE's current stock price?
What is the analyst price target for RARE?
What sector is Ultragenyx Pharmaceutical Inc. in?
What is RARE's market cap?
Does RARE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RARE for comparison